Galderma

Galderma is a major aesthetics company in the botulinum toxin market, but its role differs by product. Dysport is an Ipsen-origin abobotulinumtoxinA product; Galderma commercializes Dysport for aesthetic use in licensed territories. Relfydess is different: it is Galderma’s relabotulinumtoxinA product, approved in international markets but not FDA approved in the United States.

Those relationships should not be collapsed. Ipsen remains central to Dysport’s product origin and therapeutic franchise, while Galderma holds significant aesthetic commercialization rights. Relfydess is a separate Galderma-developed product with its own formulation, approvals, and regulatory path.

Quick Answers

Question	Short answer
Is Galderma a botulinum toxin company?	Yes, in market-structure terms. Galderma is linked to botulinum toxin through Dysport aesthetic commercialization and its own relabotulinumtoxinA product, Relfydess.
Who makes Dysport?	Dysport belongs to the Ipsen-origin abobotulinumtoxinA product family. Ipsen remains the core product-origin and manufacturing node, while Galderma commercializes aesthetic Dysport in licensed territories.
Who owns Dysport?	Dysport rights are not a single global ownership answer. Ipsen remains central to the Dysport product family, and Galderma holds important aesthetic commercialization rights in licensed markets.
Does Galderma make Dysport?	Ipsen remains the core Dysport origin and manufacturing node; Galderma commercializes Dysport for aesthetic use in licensed territories.
What is Relfydess?	Relfydess is Galderma’s brand name for relabotulinumtoxinA in approved international markets.
Is Relfydess FDA approved?	No. Galderma reported on July 1, 2026 that FDA issued a Complete Response Letter for the relabotulinumtoxinA application.

Who makes Dysport?

Ipsen is the core product-origin and manufacturing reference point for the Dysport / abobotulinumtoxinA family. Galderma’s role is commercial: it markets Dysport for aesthetic use in licensed territories, so “made by Galderma” is not the precise way to describe the product relationship.

Is Relfydess FDA approved?

No. FDA acceptance of Galderma’s February 2, 2026 BLA resubmission was a review milestone, not approval. Galderma reported on July 1, 2026 that FDA issued a Complete Response Letter for the relabotulinumtoxinA application.

Reference Card

Field	Reference point
Company	Galderma Group AG
Base	Switzerland
Website	galderma.com 🔗
Public status	SIX Swiss Exchange-listed; ticker GALD
Botulinum toxin role	Aesthetic commercialization partner for Dysport-family products in licensed territories and developer of relabotulinumtoxinA
Dysport relationship	Galderma commercializes Dysport / Azzalure and Alluzience for aesthetic use in licensed markets; Ipsen remains the core product-origin node
Galderma-developed toxin	RelabotulinumtoxinA, marketed as Relfydess in approved international markets
U.S. Relfydess status	FDA issued a Complete Response Letter reported by Galderma on July 1, 2026; Relfydess is not FDA approved

Person	Why the relationship matters
Flemming Ørnskov	Galderma’s Chief Executive Officer, connecting the company’s public-company strategy to Dysport aesthetic commercialization and Relfydess development context.

Dysport Manufacturer, Owner, and Ipsen Relationship

Ipsen developed and manufactures the abobotulinumtoxinA product family. Dysport maker or manufacturer questions therefore point first to Ipsen, not Galderma. Through long-running agreements, Galderma commercializes Dysport, Azzalure, and Alluzience for aesthetic use in licensed territories, including the United States and Canada for Dysport aesthetics.

Dysport ownership questions are more precise when separated into product origin, manufacturing, regulatory labels, and commercialization rights. The relationship is indication- and territory-specific. It does not make Galderma the universal owner or manufacturer of every Dysport presentation, and it does not make aesthetic and therapeutic labels interchangeable.

Product relationship	Galderma role	Important limit
Dysport / Azzalure / Alluzience	Licensed aesthetic commercialization in relevant territories	Product origin, manufacturing, labels, and therapeutic context remain tied to Ipsen and local approvals.
Relfydess / relabotulinumtoxinA	Galderma-developed botulinum toxin type A product	International approval does not create U.S. approval, unit equivalence, or interchangeability with other toxins.

Relfydess Development Node

Galderma developed relabotulinumtoxinA internally and markets it as Relfydess in approved international markets. The company describes it as a ready-to-use liquid botulinum toxin type A product that does not require reconstitution.

By March 2026, Galderma reported Relfydess commercial activity across multiple international markets. Market authorization conditions vary by jurisdiction, so approval in Europe or another market should not be read as U.S. approval.

Relfydess FDA Status: Not U.S. Approved

Relfydess is not FDA approved in the United States. On July 1, 2026, Galderma reported that FDA had issued a Complete Response Letter for the relabotulinumtoxinA application. Galderma said the comments related to observations during a manufacturing-site inspection and analytical-method optimization.

That U.S. CRL does not change the product’s international status. Galderma reported on the same date that Relfydess was approved in 33 markets and launched in more than 20. Product approval, indications, and availability should still be checked against local records rather than inferred from an international launch.

Market Interpretation

Galderma connects an established licensed franchise and a newer internally developed product. It is therefore both a commercialization node and a development node, but for different toxins. Keeping those roles separate prevents Dysport history from being attributed to Relfydess and prevents Relfydess regulatory status from being transferred to Dysport.